Evidence map›Paper›PMID 38683440›Full record

ReviewJournal of hematopathology2024

What is new in the 5th edition of the World Health Organization classification of mature B and T/NK cell tumors and stromal neoplasms?

Ayoma D Attygalle, John K C Chan, Sarah E Coupland, Ming-Qing Du, Judith A Ferry, Daphne de Jong, Dita Gratzinger, Megan S Lim, Alina Nicolae, German Ott and 4 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of hematopathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ayoma D AttygalleDepartment of Histopathology, The Royal Marsden Hospital, London, SW3 6JJ, UK.
John K C ChanDepartment of Pathology, Queen Elizabeth Hospital, Kowloon, Hong Kong SAR, China.
Sarah E CouplandDepartment of Molecular and Clinical Cancer Medicine, ISMIB, University of Liverpool, Liverpool, UK.
Ming-Qing DuDepartment of Pathology, University of Cambridge, Cambridge, UK.
Judith A FerryDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA. JFERRY@mgh.harvard.edu.
Daphne de JongDepartment of Pathology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
Dita GratzingerDepartment of Pathology, Stanford University School of Medicine, Stanford, USA.
Megan S LimDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
Alina NicolaeDepartment of Pathology, Hautepierre, University Hospital of Strasbourg, Strasbourg, France.
German OttDepartment of Clinical Pathology, Robert-Bosch-Krankenhaus, Auerbachstr. 110, 70376, Stuttgart, Germany. German.ott@rbk.de.
Andreas RosenwaldInstitute of Pathology, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.
Anna SchuhDepartment of Oncology, University of Oxford, Oxford, UK.
Reiner SiebertInstitute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany.
WHO 5th Edition Classification Project

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The classification of tumors is essential in the diagnosis and clinical management of patients with malignant neoplasms. The World Health Organization (WHO) provides a globally applicable classification scheme of neoplasms and it was updated several times. In this review, we briefly outline the cornerstones of the upcoming 5th edition of the World Health Organization Classification of Haematolymphoid Tumours on lymphoid neoplasms. As is adopted throughout the 5th edition of the WHO classification of tumors of all organ systems, entities are listed by a hierarchical system. For the first time, tumor-like lesions have been included in the classification, and modifications of nomenclature for some entities, revisions of diagnostic criteria or subtypes, deletion of certain entities, and introduction of new entities are presented along with mesenchymal lesions specific to the stroma of lymph nodes and the spleen. In addition to specific outlines on constitutional and somatic genetic changes associated with given entities, a separate chapter on germline predisposition syndromes related to hematologic neoplasms has been added.

Indexed as

Lymphoma, B-CellLymphoma, Extranodal NK-T-CellLymphoma, T-CellNeoplasms, Connective and Soft TissueWorld Health OrganizationHumansLymph NodesMesodermSpleen5th editionClassificationLymphomaLymphoproliferationReviewWHO

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.